Clearing up misconceptions about marijuana rescheduling: What it means for existing state systems

As marijuana rescheduling has gained traction in Congress and DEA has announced it will rule on a rescheduling this summer, a common concern has emerged in the cannabis reform community and among industry actors.  It goes something like this: “If marijuana is moved to Schedule II, the Feds will shut down our state’s legal system.” The worry is that this administrative change will make marijuana pharmaceuticals legal and thus require all such products to be removed from the market until FDA approval is granted. And of course, clinical drug testing and FDA approval often takes years and hundreds of millions (if not more) dollars in research—something cannabusinesses can’t afford and time medical marijuana patients don’t have. Read more »